Epizyme (EPZM) Tops Q3 EPS by 5c, Revenues Miss

Epizyme (NASDAQ: EPZM) reported Q3 EPS of ($0.55), $0.05 better than the analyst estimate of ($0.60). Revenue for the quarter came in at $3.57 million versus the consensus estimate of $5.43 million.

“2020 has been a year of big milestones for Epizyme, and we are executing our TAZVERIK® launches well, given the unprecedented challenges presented by the COVID-19 pandemic on FL patients’ access to their physicians and on access to our customers,” said Robert Bazemore, president and chief executive officer of Epizyme. “While we acknowledge the impact the COVID-19 dynamics have had on the initial uptake in FL, we are reaching both the ES and FL patient populations expected based on our label, and our view of the value proposition of TAZVERIK is unchanged. We believe that the combination of our commercial and clinical performance, and strong balance sheet, sets us up for a positive future.”

For earnings history and earnings-related data on Epizyme (EPZM) click here.

You May Also Be Interested In

• Citi agrees to acquire rewards platform Kard Financial
• Boqii says no new developments behind unusual trading activity
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c